部分抗肿瘤药物基因组学研究进展

中国临床药理学与治疗学 ›› 2009, Vol. 14 ›› Issue (6): 701-706.

部分抗肿瘤药物基因组学研究进展

华之卉^1,2, 侯颖^1,2, 宋洪涛¹

¹南京军区福州总医院药学科, 福建 350025, 福州;
²沈阳药科大学药学院, 沈阳 110016, 辽宁

收稿日期:2009-05-12 修回日期:2009-06-11 出版日期:2009-06-26 发布日期:2020-10-27
通讯作者: 宋洪涛, 男, 博士, 主任药师, 硕士生导师, 研究方向:药剂学、临床药学。Tel:0591-22859459 E-mail:sohoto@vip.sohu.com
作者简介:华之卉,女,硕士研究生,研究方向:临床药学。Tel:15998335211 E-mail:zhihui19998@126.com

Advancement on pharmacogenomics of partial antitumor drugs

HUA Zhi-hui^1,2,HOU Ying^1,2, SONG Hong-tao¹

¹Department of Pharmacy, Fuzhou General Hospital of Nanjing Military Region, Fujian 350025, Fuzhou, China;
²College of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, Liaoning, China

Received:2009-05-12 Revised:2009-06-11 Online:2009-06-26 Published:2020-10-27

摘要/Abstract

摘要： 近年来, 由于个体差异引起抗肿瘤药物疗效和毒副作用的不同受到越来越多的重视。药物基因组学的研究结果表明基因多态性与抗肿瘤药物个体间作用多样性及毒副作用之间的关系密切。本文就部分抗肿瘤药物基因组学的研究进展加以综述。

关键词: 药物基因组学, 抗肿瘤药物, 基因多态性

Abstract: Recently, diverse effects and side effects of antitumor drugs induced by individual difference have received considerable attention.Studies on pharmacogenomics show that genomic polymorphism is closely associated with individual difference and side effects of antitumor drugs.The paper summarizes the advancement on pharmacogenomics of partial antitumor drugs.

Key words: pharmacogenomics, antitumor drug, genomic polymorphism

中图分类号:

R73-3

华之卉, 侯颖, 宋洪涛. 部分抗肿瘤药物基因组学研究进展[J]. 中国临床药理学与治疗学, 2009, 14(6): 701-706.

HUA Zhi-hui,HOU Ying, SONG Hong-tao. Advancement on pharmacogenomics of partial antitumor drugs[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2009, 14(6): 701-706.

参考文献

[1] 魏嘉, 王立峰, 刘宝瑞.5-FU 相关的药物疗效及毒性预测分子研究进展[J].世界华人消化杂志, 2005, 13(15):1889-1893.
[2] Saif MW, Ezzeldin H, Vance K, et al.DPYD * 2A mutation:the most common mutation associated with DPD deficiency[J].Cancer Chemother Pharmacol, 2007, 60(4): 503-507.
[3] Zhang H, Li YM, Zhang H, et al.DPYD* 5 gene mutation contributes to the reduced DPYD enzyme activity and chemotherapeutic toxicity of 5-FU:results from genotyping study on 75 gastric carcinoma and colon carcinoma patients [J].Med Oncol, 2007, 24(2):251-258.
[4] Morel A, Boisdron-Celle M, Fey L, et al.Identification of a novel mutation in the dihydropyrimidine dehydrogenase gene in a patient with a lethal outcome following 5-fluorouracil administration and the determination of its frequency in a population of 500 patients with colorectal carcinoma [J].Clin Biochem, 2007, 40(1/2):11-17.
[5] Amatori F, Di Paolo A, Del Tacca M, et al.Thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer and normal mucosa in patients[J].Pharmacogenet Genomics, 2006, 16(11):809-816.
[6] Huang ZH, Hua D, Li LH.The polymorphisms of TS and MTHFR predict survival of gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy in Chinese population[J].Cancer Chemother Pharmacol, 2009, 63 (5):911-918.
[7] Sasaki S,Watanabe T, Kobunai T, et al.Effect of cystathionine beta-synthase variant 844ins68bp and methylenetetrahydrofolate reductase A1298C polymorphisms in xenografts on 5-FU efficacy and doubling time[J].Cancer Lett, 2006, 241(2):256-262.
[8] Gisbert JP, Gomollon F, Cara C, et al.Thiopurine methyltransferase activity in Spain:a study of 14, 545 patients [J].Dig Dis Sci, 2007, 52(5):1262-1269.
[9] Innocenti F, Iyer L, RatainMJ.Pharmacogenetics:a tool for individualizing antineoplastic therapy[J].Clin Pharmacokinet, 2000, 39(5):315-325.
[10] Ma XL, Zhu P,Wu MY, et al.Relationship between single nucleotide polymorphisms in thiopurine methyltransferase gene and tolerance to thiopurines in acute leukemia[J]. Zhonghua Er Ke Za Zhi, 2003, 41(12):929-933.
[11] Dokmanovic L, Urosevic J, Janic D, et al.Analysis of thiopurine S-methy ltransferase polymorphism in the population of Serbia and Montenegro and mercaptopurine therapy tolerance in childhood acute lymphoblastic leukemia[J].Ther Drug Monit, 2006, 28(6):800-806.
[12] 府伟灵, 黄庆.肿瘤个体化治疗[J].重庆医学, 2008,37(3):225-226.
[13] 刘健雄, 马志明.ERCC1 表达水平与晚期非小细胞肺癌患者化疗疗效的相关性[J].实用医学杂志,2008, 24(15):2551-2554.
[14] Liu GY, Qu QX, Mi RR, et al.Relationship between nucleotide excision repair gene ERCC1 and resistance to cisplatin in ovarian cancer[J].Zhonghua Zhong Liu Za Zhi, 2008, 30(3):184-187.
[15] Krivak TC, Darcy KM, Tian C, et al.Relationship between ERCC1 polymorphisms, disease progression, and survival in the Gynecologic Oncology Group Phase III Trial of intraperitoneal versus intravenous cisplatin and paclitaxel for stage III epithelial ovarian cancer [J].J Clin Oncol, 2008, 26(21):3598-3606.
[16] Kamikozuru H, Kuramochi H, Hayashi K, et al.ERCC1 codon 118 polymorphism is a useful prognostic marker in patients with pancreatic cancer treated with platinum-based chemotherapy[J].Int Oncol, 2008, 32(5):1091-1096.
[17] Wang ZH, Miao XP, Tan W, et al.Single nucleotide polymorphisms in XRCC1 and clinical response to platin-based chemotherapy in advanced non-small cell lung cancer[J]. Ai Zheng, 2004, 23(8):865-868.
[18] Giachino DF, Ghio P, Reqazzoni S, et al.Prospective assessment of XPD Lys751Gln and XRCC1 Arg399Gln single nucleotide polymorphisms in lung cancer[J].Clin Cancer Res, 2007, 13(10):2876-2881.
[19] Wang Z, Xu B, Lin D, et al.XRCC1 polymorphisms and severe toxicity in lung cancer patients treated with cisplatin-based chemotherapy in Chinese population[J].Lung Cancer, 2008, 62(1):99-104.
[20] Kweekel DM, Gelderblom H, Gelderblom H, et al. UGT1A1* 28 genotype and irinotecan dosage in patients with metastatic colorectal cancer:a Dutch colorectal cancer group study[J].Br J Cancer, 2008, 99(2):275-282.
[21] Liu JY, Qu K, Sferruzza AD, et al.Distribution of the UGT1A1* 28 polymorphism in Caucasian and Asian populations in the US:a genomic analy sis of 138 healthy individuals[J].Anticaner Drugs, 2007, 18(6):693-696.
[22] Stewart CF, Panetta JC, Oshauqhnessy MA, et al.UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving Low-dose irinotecan[J].J Clin Oncol, 2007, 25(18):2594-2600.
[23] Jada SR, Lim R, Wong CI, et al.Role of UGT1A1* 6, UGT1A1* 28 and ABCG2 c.421C>A polymorphisms in irinotecan-induced neutropenia in Asian cancer patients [J].Cancer Sci, 2007, 98(9):1461-1467.
[24] Yamaoto N, Takahashi T, Kunikane H, et al.Phase I II pharmacokinetic and pharmacogenomic study of UGT1A1 polymorphism in elderly patients with advanced non-small cell lung cancer treated with irinotecan[J].Clin Pharmacol Ther, 2009, 85(2):149-154.
[25] Ando Y, Fujita K, Sasaki Y, et al.UGT1A1* 6 and UGT1A1 * 27 for individualized irinotecan chemotherapy [J].Curr Opin Ther, 2007, 9(3):258-262.
[26] Fujita K, Ando Y, Naqashima F, et al.Genetic linkage of UGT1A7 and UGT1A9 polymorphisms to UGT1A1 * 6 is associated with reduced activity for SN-38 in Japanese patients with cancer [J].Cancer Chemother Pharmacol, 2007, 60(4):515-522.
[27] Satio Y, Sai K, Maekawa K, et al.Close association of UGT1A9 IVS1+399C>T with UGT1A1* 28, * 6, or* 60 haplotype and its apparent influence on 7-ethyl-10-hydroxycamptothecin (SN-38) glucuronidation in Japanese [J].Drug Metab Dispos, 2009, 37(2):272-276.
[28] Fujita K, Sasaki Y.Pharmacogenomics in drug-metabolizing enzymes catalyzing anticancer drugs for personalized cancer chemotherapy[J].Curr Drug Metab, 2007, 8(6):554-562.
[29] Schroth W, Antoniadou L, Fritz P, et al.Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes[J].J Clin Oncol, 2007, 25(33):5187-5193.
[30] Xu Y, Sun Y, Yao L, et al.Association between CYP2D6 * 10 genotype and survival of breast cancer patients receiving tamoxifen treatment[J].Ann Oncol, 2008, 19(8):1423-1429.
[31] Mortimer JE, Flatt SW, Park BA, et al.Tamoxifen, hot flashes and recurrence in breast cancer[J].Breast Cancer Res Treat, 2008, 108(3):421-426.